Efficacy of subantimicrobial-dose doxycycline in the treatment of periodontal diseases: A critical evaluation

International Journal of Periodontics and Restorative Dentistry

Volumn 24, Issue 6, 2004, Pages 528-543

  Greenstein, Gary ^a,b  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; DOXYCYCLINE; METRONIDAZOLE; POVIDONE IODINE; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; CHRONIC DISEASE; CLINICAL TRIAL; DEBRIDEMENT; DIABETES MELLITUS; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG USE; EVALUATION; GINGIVA BLEEDING; HUMAN; INCIDENCE; MECHANICAL PROBE; NONHUMAN; PERIODONTAL DISEASE; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; SMOKING; STATISTICAL SIGNIFICANCE;

ANTI-BACTERIAL AGENTS; CHRONIC DISEASE; CLINICAL PROTOCOLS; COMBINED MODALITY THERAPY; CONTROLLED CLINICAL TRIALS; DISEASE PROGRESSION; DOXYCYCLINE; GINGIVAL HEMORRHAGE; HUMANS; PERIODONTAL ATTACHMENT LOSS; PERIODONTAL DISEASES; PERIODONTAL POCKET; PERIODONTITIS;

EID: 8744307272     PISSN: 01987569     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. American Academy of Periodontology. The pathogenesis of periodontal diseases. J Periodontol 1999;70:457-470.
2. Offenbacher S. Periodontal diseases: Pathogenesis. Ann Periodontol 1996;1:821-878.
3. Page RC, Offenbacher S, Schroeder HE, Seymour GJ, Kornman KS. Advances in the pathogenesis of periodontitis: Summary of developments, clinical implications and future direction. Periodontol 2000 1997;14:216-248.
4. Golub LM, Wolff M, Lee HM, et al. Further evidence that tetracyclines inhibit collagenase activity in human crevicular fluid and from other mammalian sources. J Periodontal Res 1985;20:12-23.
5. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998;12:12-26.
6. Crout RJ, Lee HM, Schroeder K, et al. The "cyclic" regimen of low-dose doxycycline for adult periodontitis: A preliminary study. J Periodontol 1996;67:506-514.
7. Caton JG, Ciancio SG, Bleiden TM, et al. Treatment with subantimicrobial dose doxycycline improves the efficacy of scaling and root planing in patients with adult periodontitis. J Periodontol 2000;71:521-532.
8. Greenstein G, Lamster I. Efficacy of periodontal therapy: Statistical versus clinical significance [editorial]. J Periodontol 2000;71:657-662.
9. Lefort SM. The statistical versus clinical significance debate. Image 1993;25:57-62.
10. Caton JG, Ciancio SG, Bleiden TM, et al. Subantimicrobial dose doxycycline as an adjunct to scaling and root planing: Post-treatment effects. J Clin Periodontol 2001;28:782-789.
11. Novak MJ, Johns LP, Miller RC, Bradshaw MH. Adjunctive benefits of subantimicrobial dose doxycycline in the management of severe, generalized, chronic periodontitis. J Periodontol 2002;73:762-769.
12. Golub LM, McNamara TF, Ryan ME, et al. Adjunctive treatment with subantimicrobial doses of doxycycline: Effects on gingival fluid collagenase activity and attachment loss in adult periodontitis. J Clin Periodontol 2001;28:146-156.
13. Ciancio S, Ashley R. Safety and efficacy of sub-antimicrobial dose doxycycline therapy in patients with adult periodontitis. Adv Dent Res 1998;12:27-31.
14. Preshaw PM, Hefti AF, Novak MJ, et al. Subantimicrobial dose doxycycline enhances scaling and root planing [abstract 841]. J Dent Res 2002;81.
15. Gapski R, Barr JL, Sarment DP, Layher MG, Socransky SS, Giannobile WV. Effect of systemic matrix metalloproteinase inhibition on periodontal wound repair: A proof of concept trial. J Periodontol 2004;75:441-452.
16. Walker C, Thomas J, Nango S, Lennon J, Wetzel J, Powala C. Long-term treatment with subantimicrobial dose doxycycline exerts no antibacterial effect on the subgingival microflora associated with adult periodontitis. J Periodontol 2000;71:1465-1471.
17. Pflug P, Haffajee AD, Torresyap G, Guerrero DM, Socransky SS. Comparison of 3 systemic antimicrobial therapies [abstract 527]. J Dent Res 2003;82.
18. Engebretson SP, Hey-Hadavi J, Celenti R, Lamster IB. Low-dose doxycycline treatment reduces glycosylated hemoglobin in patients with type 2 diabetes: A randomized controlled trial [abstract 1445]. J Dent Res 2003;82.
19. Al-Ghazi MN, Ciancio SG, Aljada A, et al. Evaluation of efficacy of administration of sub-antimicrobial-dose doxycycline in the treatment of generalized adult periodontitis in diabetics [abstract 1752]. J Dent Res 2003;82.
20. Mohammad AR, Preshaw PM, Hefti AF, Bradshaw M, Powala CV. Subantimicrobial-dose doxycycline for treatment of periodontitis in an institutionalized geriatric population [abstract 2701]. J Dent Res 2003;82.
21. Jeffcoat MK. Principles and pitfalls of clinical trials. J Periodontol 1992;63:1045-1051.
22. Greenwald RA. Treatment of destructive disorders with MMP inhibitors: Potential role of tetracyclines. Ann N Y Acad Sci 1994;732:181-198.
23. Hung HC, Douglass CW. Meta-analysis of the effect of scaling and root planing, surgical treatment and antibiotic therapies on periodontal probing depth and attachment loss. J Clin Periodontol 2002;29:975-986.
24. Cobb CM. Non-surgical pocket therapy: Mechanical. Ann Periodontol 1996;1:443-490.
25. McQuay HJ, Moore RA. Using numerical results for systematic reviews in clinical practice. Ann Intern Med 1997;126:712-720.
26. Lindhe J, Okamoto H, Yoneyama T, Haffajee A, Socransky SS. Periodontal loser sites in untreated adult subjects. J Clin Periodontol 1989;16:671-678.
27. Grbic JR, Lamster IB, Celenti RS, Fine JB. Risk indicators for future clinical attachment loss in adult periodontitis. Patient variables. J Periodontol 1991;62:322-329.
28. Deas D, Pasquali L, Yuan CH, Kornman KS. The relationship between probing attachment loss and computerized radiographic analysis in monitoring progression of periodontitis. J Periodontol 1991;62:135-141.
29. Preshaw PM, Bradshaw MH, Hefti AF, Powala CV, Ashley RA. Adjunctive subantimicrobial-dose doxycycline for treatment of smokers with periodontitis [abstract 1739]. J Dent Res 2003;82.
30. Drisko CL, Cobb CM, Killoy WJ, et al. Evaluation of periodontal treatments using controlled-release tetracycline fibers: Clinical response. J Periodontol 1995;66:692-699.
31. Williams RC, Paquette DW, Offenbacher S, et al. Treatment of periodontitis by local administration of minocycline microspheres: A controlled trial. J Periodontol 2001;72:1535-1544.
32. Loesche WJ, Giordano JR, Hujoel P, Schwarcz J, Smith BA. Metronidazole in periodontitis: Reduced need for surgery. J Clin Periodontol 1992;19:103-112.
33. Loesche WJ, Schmidt E, Smith BA, Morrison EC, Caffesse R, Hujoel PP. Effects of metronidazole on periodontal treatment needs. J Periodontol 1991;62:247-257.
34. Rosling BG, Slots J, Christersson LA, Grondahl HG, Genco RJ. Topical antimicrobial therapy and diagnosis of subgingival bacteria in the management of inflammatory periodontal disease. J Clin Periodontol 1986;13:975-981.
35. Magnusson I, Low SB, McArthur WP, et al. Treatment of subjects with refractory periodontal disease. J Clin Periodontol 1994;21:628-637 [erratum 1995;22:183].
36. Magnusson I, Lindhe H, Yoneyama T, Liljenberg B. Recolonization of a subgingival microbiota following scaling in deep pockets. J Clin Periodontol 1984;11:193-207.
37. Torfason T, Kiger R, Selvig KA, Egelberg J. Clinical improvement of gingival conditions following ultrasonic versus hand instrumentation of periodontal pockets. J Clin Periodontol 1979;6:165-176.
38. Listgarten MA, Lindhe J, Hellden LB. Effect of tetracycline and/or scaling on human periodontal disease. J Clin Periodontol 1978;5:246-271.
39. Thomas J, Walker C, Bradshaw M. Use of subantimicrobial dose doxycycline does not lead to changes in antimicrobial susceptibilities. J Periodontol 2000;71:1472-1483.
40. Sakellari D, Goodson JM, Kolokotronis A, Konstantinidis A. Concentration of 3 tetracyclines in plasma, gingival crevicular fluid, and saliva. J Clin Periodontol 2000;27:53-60.
41. Gordon JM, Walker CB, Murphy JC, Goodson JM, Socransky SS. Concentration of tetracycline in human gingival fluid after single doses. J Clin Periodontol 1981;8:117-121.
42. Gordon JM, Walker CB, Murphy JC, Goodson JM, Socransky SS. Tetracycline: Levels achievable in gingival crevice fluid and in vitro effect on subgingival organisms. Part I - Concentrations in crevicular fluid after repeated doses. J Periodontol 1981;52:609-612.
43. Pascale D, Gordon J, Lamster I, Mann P, Seiger M, Arndt W. Concentration of doxycycline in human gingival fluid. J Periodontol 1986;13:841-844.
44. Mandel GL, Bennet SE, Dolin R. Basic principles in the diagnosis and management of infectious disease. In: Principles and Practice of Infectious Diseases, ed 4. New York: Churchill Livingstone, 1994: 308.
45. Reddy MS, Gears NC, Gunsolley JC. Periodontal host modulation with antiproteinases, anti-inflammatory, and bone sparing agents. A systematic review. Ann Periodontol 2003;8:12-37.
46. Emingil G, Atilla G, Sorsa T, Luoto H, Kirilmaz L, Baylas H. The effect of adjunctive low-dose doxycycline therapy on clinical parameters and gingival crevicular fluid matrix metalloproteinase-8 levels in chronic periodontitis. J Periodontol 2004;75:106-115.
47. Choi DH, Moon IS, Choi BK, et al. Effects of sub-antimicrobial dose doxycycline therapy on crevicular fluid MMP-8, and gingival tissue MMP-9, TIMP-1 and IL-6 levels in chronic periodontitis. J Periodontal Res 2004;39:20-26.
48. Lee HM, Ciancio SG, Tuter G, Ryan ME, Komaroff E, Golub LM. Subantimicrobial dose doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic periodontitis patients is enhanced when combined with a non-steroidal anti-inflammatory drug. J Periodontol 2004;75:453-463.
49. Brown DL, Desai KK, Vakili BA, Nouneh C, Lee HM, Golub LM. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol 2004;24:733-738.
50. Pflug P, Haffajee AD, Torresyap G, et al. Changes following different antimicrobial therapies at 6 months. 1. Clinical [abstract 1461]. J Dent Res 2004;83.